Expand SYRE Menu
SYRE MENU

SYRE Latest Press Releases

-- April 4, 2025 --

Spyre Therapeutics Announces Grants of Inducement Awards PRNewswire 4:05 PM

-- March 27, 2025 --

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody PRNewswire 4:05 PM

-- March 7, 2025 --

Spyre Therapeutics Announces Grants of Inducement Awards PRNewswire 4:40 PM

-- February 27, 2025 --

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update PRNewswire 4:05 PM

-- February 25, 2025 --

Spyre Therapeutics to Participate in Upcoming March Investor Conferences PRNewswire 8:00 AM

-- February 19, 2025 --

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation PRNewswire 8:00 AM

-- February 7, 2025 --

Spyre Therapeutics Announces Grants of Inducement Awards PRNewswire 5:13 PM

-- February 4, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 5:15 PM

-- January 28, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 12:10 PM

-- January 21, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 7:10 PM

-- January 13, 2025 --

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts PRNewswire 8:00 AM

-- January 8, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 12:00 PM

-- January 3, 2025 --

Spyre Therapeutics Announces Grants of Inducement Awards PRNewswire 5:20 PM

-- January 2, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 10:55 AM

-- December 27, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 5:10 PM

-- December 18, 2024 --

Spyre Therapeutics Added to the Nasdaq Biotechnology Index PRNewswire 8:00 AM

-- December 3, 2024 --

SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 7:23 PM

-- December 2, 2024 --

Spyre Therapeutics Announces Grants of Inducement Awards PRNewswire 5:03 PM
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies PRNewswire 8:00 AM

-- November 25, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PRNewswire 8:05 PM
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PRNewswire 5:11 PM

-- November 18, 2024 --

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PRNewswire 9:19 PM
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PRNewswire 4:14 PM

-- November 12, 2024 --

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing PRNewswire 7:30 AM

-- November 11, 2024 --

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-a47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 PRNewswire 4:05 PM